484 Results (Page 16 of 20)
UAE Markets Research Reports
UAE Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis
UAE Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
UAE Multiple Sclerosis Drugs Market Analysis
UAE Multiple Sclerosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Multiple sclerosis is rising due to increase in Incidence and prevalence of multiple sclerosis (MS), Improved diagnosis and awareness, advancements in healthcare infrastructure , Advancements in Treatment Options, Expanding Pipeline of Innovative Therapies, technological advancements and increase in funding for research of multiple sclerosis. Major global players in Multiple Sclerosis Drugs Market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)
UAE Myasthenia Gravis Drugs Market Analysis
UAE Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis
UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
UAE Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis
UAE Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.
UAE POMC Genetic Obesity Drugs Market Analysis
UAE POMC Genetic Obesity Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for POMC Genetic Obesity Drugs is growing due to increase spending in research and development activities by pharmaceutical companies, introduction of new emerging therapies like gene editing and gene replacement approaches, incentives provided by regulatory body?s in the form of orphan drug designations. Novo Nordisk A/S , rhythm Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated ,Amgen Inc are the key market players operating in global POMC genetic obesity drugs market.
UAE Pompe Disease Drugs Market Analysis
UAE Pompe Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pompe disease Drugs is growing due to increase in awareness about the disease , better diagnosis, advancements in treatment options and increase in research and development activities by different pharmaceutical companies and research organizations. Sanofi Genzyme ,BioMarin Pharmaceutical Inc., Avrobio Inc., Amicus Therapeutics Inc. are the key market players operating in global pompe disease market.
UAE Primary Hyperoxaluria (PH) Drugs Market Analysis
UAE Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
UAE Pyruvate Kinase (PK) Deficiency Market Analysis
UAE Pyruvate Kinase (PK) deficiency market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pyruvate Kinase (PK) deficiency is growing rapidly as a result of increase in incidence and prevalence of disease, increased awareness about the disease, improved diagnostic techniques, advancements in treatment options, increase in research and development and rise in patient assistance programmes. Agios pharmaceuticals, Pfizer Inc., Sanofi, Novartis, Teva Pharmaceutical Industries Ltd, Green cross corporation are the top key market players operating in the global Pyruvate Kinase (PK) deficiency market.
UAE Rare Hematology Disorders Market Analysis
UAE Rare Hematology Disorders market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hematology Disorders is growing rapidly as a result of increase in incidence of rare blood disorders, increase in awareness of rare hematology disorders, advancement in genetic testing and diagnostic techniques, increase in spending on healthcare infrastructure and increasing adoption of gene therapy. Sanofi Genzyme, Pfizer Inc., Novartis AG, Alexion Pharmaceuticals, Shire., BioMarin Pharmaceutical Inc., CSL Behring are the key global market players operating in rare hematology disorders market.
UAE Rare Hemophilia Factors Market Analysis
UAE Rare Hemophilia Factors market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hemophilia Factors is growing rapidly as a result of growing incidence of rare hemophilia factors deficiency, rising adoption of prophylactic treatments, growing awareness about rare hemophilia factors and their treatment options, rising demand for better and more effective therapies for rare hemophilia factors. Baxter, Bayer AG, Bio Products Laboratory Ltd., Novo Nordisk A/S, Alexion Pharmaceuticals, Amgen Inc, BioMarin, Amgen Inc are the key global market players operating in rare hemophilia factors market.
UAE Rett Syndrome Drugs Market Analysis
UAE Rett Syndrome Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending for patient advocacy and rising global healthcare expenditure. Major global players in Rett Syndrome Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
UAE Sickle Cell Disease Drugs Market Analysis
UAE Sickle cell disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sickle cell disease Drugs is growing rapidly as a result of increasing prevalence of sickle cell disease , increasing investment for healthcare infrastructure, increase in the number of research and development activities, Support provided by governments of different countries, patient advocacy programmes and incentives provided by regulatory authorities. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.
UAE Soft Tissue Sarcoma Market Analysis
UAE Soft Tissue Sarcoma market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Soft Tissue Sarcoma is growing rapidly as a result of increasing prevalence and incidence of soft tissue sarcoma, rising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics. Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, Bayer AG, Eisai Co., Ltd., Epizyme, Inc., Adaptimmune Therapeutics, Mylan N.V., Sanofi are the key market players operating in global Soft Tissue Sarcoma market.
UAE Wilson's Disease Drugs Market Analysis
UAE Wilson?s Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Wilson?s Disease Drugs is growing rapidly as a result of rising prevalence of the disease, advancements in diagnostic techniques , increase in awareness about the disease due to patient advocacy programmes , support and incentives from regulatory authorities like incentives and orphan drug designations and increasing investment in research and development activities. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd. , Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., Mylan pharmaceuticals are the key global market players in wilson?s disease drugs market.
UAE X-Linked Myotubular Myopathy (XLMTM) Drugs Market Analysis
UAE X-Linked Myotubular Myopathy (XLMTM) Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for X-Linked Myotubular Myopathy (XLMTM) Drugs is growing rapidly as a result of unmet medical need for therapies of X-Linked Myotubular Myopathy (XLMTM) disease, advancements in gene therapy, Growing Awareness and Patient Advocacy about the disease, Increased Research and Collaboration between research organizations and pharmaceutical companies, supportive regulatory environments, Technological Advancements in gene sequencing and biomarker identification. Novartis Gene Therapies, Avrobio, Axovant Gene Therapies, Sarepta Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Pfizer, Audentes Therapeutics are the key market players operating in global X-Linked Myotubular Myopathy (XLMTM) Drugs market.
UAE Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
UAE Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $91 Mn in 2022 and is estimated to expand at a CAGR of 8.1% from 2022-30 and will reach $170 Mn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate and government initiative. The market is segmented by Drug class and By distribution channel. Some key players in this market are Julphar, Neopharma,b Global Pharma, Medpharma, Pharmaforte, Abbott Laboratories, Almirall, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva Pharmaceuticals and others.
UAE Robotic Surgery Services Market Analysis
The UAE Robotic Surgery Service market size was valued at $21 Mn in 2022 and is estimated to expand at a CAGR of 20.3% from 2022-30 and will reach $94 Mn in 2030. The market will grow due to the growing patient population and greater usage of sophisticated automated surgical equipment. The market is segmented by product and service type, application type, and end user. Some of the major players are Dubai Robotics (UAE), Axiom Robotics (UAE), Emirates (UAE), Next Future Transportation (UAE), Adarma (UAE), and others.
UAE Alexipharmic Drugs Market Analysis
The UAE Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 5.70% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The UAE Alexipharmic Drugs market will grow because of growing awareness about the benefits of alexipharmic drugs among healthcare professionals and patients. The key market players are Julphar (UAE), Neopharma (UAE), Global Pharma (UAE), Pfizer Inc., and others.
UAE Diagnostic Imaging Services Market Analysis
The UAE Diagnostic Imaging Services market size was valued at $2.62 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $4.15 Bn in 2030. The market is segmented by product, application, and end user. The UAE Diagnostic Imaging Services market will grow the prevalence of chronic diseases is rising, demand for minimally invasive operations is rising. The key market players are Emirates Hospitals Group (UAE), Neusoft Medical Systems Middle East FZ LLC (UAE), Emirates Healthcare Group LLC (UAE), NMC Health Plc (UAE), Gulf Imaging and Radiology (UAE), and others.
UAE Dermatology Drugs Market Analysis
By 2030, it is anticipated that the UAE Dermatology drugs market will reach a value of $207.47 Mn from $85 Mn in 2022, growing at a CAGR of 11.8% during 2022-2030. The market is primarily dominated by local players such as Gulf Pharmaceutical Industries, Neopharma, and Julphar. The market is driven by slow research and development, increasing disease prevalence, and government regulations. The dermatology drug market in UAE is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.
UAE Electronic Health Records Market Analysis
The UAE Electronic Health Record (EHR) market size was valued at $152 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 17.5% from 2022 to 2030 and will reach $552 Mn in 2030. The market is segmented by product, application, and end user. The UAE EHR market will grow due to the Increasing adoption of digital health solutions. The key market players are IDC Salud, Cegedim, Siemens Healthineers, Cerner, and others.
UAE Dialysis Market Analysis
The UAE Dialysis Market is projected to grow from $0.581 Bn in 2022 to $1.036 Bn by 2030, registering a CAGR of 7.5% during the forecast period of 2022-2030. The increasing awareness about the importance of kidney health and the availability of treatments is also expected to drive the growth of the dialysis market in the UAE. Fresenius Medical Care is one of the leading providers of dialysis products and services in the UAE, with a significant presence in the market.
UAE Clinical Diagnostics Market Analysis
UAE clinical diagnostic market was valued at $345 Mn in 2022 and is estimated to expand at a CAGR of 7% from 2022-30 and will reach $592 Mn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic disease and government support. The market is segmented by type, drug, and distribution channel. Some key players in this market are Al Borg Laboratories, Aster DM, National Reference Laboratory, Fujifilm Middle Eas, Al Zahrawi Medical, Gulf Medical University, Life Medical Diagnostics, Abbott, BD, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, Siemens F. Hoffmann-La Roche Ltd, and others.
UAE Nutritional Supplements Market Analysis
By 2030, it is anticipated that the UAE nutrition and supplements market will reach a value of $3.94 Bn from $1.91 Bn in 2022, growing at a CAGR of 9.5% during 2022-30. The market is primarily dominated by local players such as Vitabiotics Ltd, Bayer Middle East, and Forever Living Products. The market for nutrition and supplements in the UAE is primarily driven by reimbursement scenarios, increasing consumer awareness for health and lifestyle, and international supplements business. The UAE nutrition and supplements market in UAE is segmented by Type, Product, application, and Distribution Channel.